The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

  • Olivier Tournilhac - , Université Clermont Auvergne (Author)
  • Michel van Gelder - , Maastricht University Medical Centre (UMC+) (Author)
  • Dirk Jan Eikema - , EBMT Statistical Unit (Author)
  • Nienke Zinger - , EBMT Leiden Study Unit (Author)
  • Peter Dreger - , Heidelberg University  (Author)
  • Martin Bornhäuser - , University Cancer Centre, Department of internal Medicine I (Author)
  • Vladan Vucinic - , Medical Clinic and Policinic 1 (Author)
  • Christof Scheid - , University of Cologne (Author)
  • Jan J. Cornelissen - , Erasmus University Rotterdam (Author)
  • Thomas Schroeder - , University of Duisburg-Essen (Author)
  • Pavel Jindra - , Charles University Prague (Author)
  • Henrik Sengeloev - , Bone Marrow Transplant Unit L 4043 (Author)
  • Stephanie Nguyen Quoc - , Sorbonne Université (Author)
  • Matthias Stelljes - , University of Münster (Author)
  • Igor Wolfgang Blau - , Charité – Universitätsmedizin Berlin (Author)
  • Jiri Mayer - , Masaryk University (Author)
  • Shankara Paneesha - , University Hospitals Birmingham NHS Foundation Trust (Author)
  • Patrice Chevallier - , Université de Nantes (Author)
  • Edouard Forcade - , Regional Centre for Prevention of Healthcare Associated Infections (Author)
  • Nicolaus Kröger - , University of Hamburg (Author)
  • Didier Blaise - , Programme de Transplantation & Therapie Cellulaire (Author)
  • John Gribben - , Barts Health NHS Trust (Author)
  • Bendt Nielsen - , Aarhus University (Author)
  • Jan Erik Johansson - , University of Gothenburg (Author)
  • Charalampia Kyriakou - , University College London Hospitals NHS Foundation Trust (Author)
  • Yves Beguin - , University of Liege (Author)
  • Pietro Pioltelli - , Azienda Ospedaliera San Gerardo Monza (Author)
  • Antònia Sampol - , Balearic Island Health Research Institute (Author)
  • Donal P. McLornan - , University College London Hospitals NHS Foundation Trust (Author)
  • Johannes Schetelig - , Department of internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Patrick J. Hayden - , Trinity College Dublin (Author)
  • Ibrahim Yakoub-Agha - , University Hospital of Lille (Author)

Abstract

Allogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009–2019 EBMT registry. The yearly number of allo-HCT raised to 458 in 2011 yet dropped from 2013 onwards to an apparent plateau above 100. Within the 10 countries who were under the EMA for drug approval and performed 83.5% of those procedures, large initial differences were found but the annual number converged to 2–3 per 10 million inhabitants during the 3 most recent years suggesting that allo-HCT remains applied in selected patients. Long-term follow-up on targeted therapies shows that most patients relapse, some early, with risk factors and resistance mechanisms being described. The treatment of patients exposed to both BCL2 and BTK inhibitors and especially those with double refractory disease will become a challenge in which allo-HCT remains a solid option in competition with emerging therapies that have yet to demonstrate their long-term effectiveness.

Details

Original languageEnglish
Pages (from-to)621-624
Number of pages4
JournalBone marrow transplantation
Volume58
Issue number6
Publication statusPublished - Jun 2023
Peer-reviewedYes

External IDs

PubMed 36977926

Keywords

ASJC Scopus subject areas

Keywords

  • Humans, Leukemia, Lymphocytic, Chronic, B-Cell/therapy, Hematopoietic Stem Cell Transplantation/methods, Neoplasm Recurrence, Local, COVID-19/etiology, Transplantation, Homologous/methods, Transplantation Conditioning/methods, Retrospective Studies